Advertisement
YOU ARE HERE: LAT HomeCollectionsBayer Corp

Bayer in Settlement Talks on Overbilling Charge

Pharmaceuticals: A deal could force the industry to change its drug-pricing practices, some experts say.

May 11, 2000|From Bloomberg News

WASHINGTON — Bayer Pharmaceuticals, a U.S.-based unit of Bayer, Germany's biggest drug maker, has begun settlement talks with federal and state officials about allegations that Medicare and Medicaid government health insurance programs have been overcharged for dozens of drugs.

More than a dozen drug makers, including Glaxo Wellcome and Bristol-Myers Squibb Co., have been subpoenaed in the 3-year-old Justice Department investigation. A 1997 federal Inspector General report said Medicare paid about $450 million too much for 22 prescription drugs in 1996 because of reliance on industry pricing lists.


Advertisement

The settlement talks come as Congress and President Clinton are considering expanding Medicare drug coverage, which would force drug makers to offer discounted prices. On Wednesday, Clinton and congressional Democrats offered a plan that would allow Medicare patients to defray prescription drug costs through a subsidized insurance option that would pay as much as half of drug costs up to $5,000. Beneficiaries would pay at least $26 a month in premiums.

Concerns about such legislative changes drove pharmaceutical stocks down earlier this year and are likely to do so again as the November presidential election approaches, analysts said.

On Wednesday, Bayer's American depositary receipts fell 50 cents to close at $39.38; On the New York Stock Exchange, Bristol-Myers rose 6 cents to close at $53.69 and Glaxo Wellcome's U.S. shares fell $1.80 to close at $58.07.

A settlement with Bayer could help the government force the industry to change its pricing practices, said William Sarraille, a Washington health lawyer.

"The government is looking to make an impact on changing the way [drug companies] sell and market their products," he said.

Bayer is the only company so far to say it is in settlement talks.

"It was in the best interest of everyone to settle rather than litigate, which is expensive and counterproductive for everyone involved," said Daniel McIntyre, a spokesman for Bayer Pharma North America. "We have always maintained that we operated within the letter and spirit of the law."

Bristol-Myers, a maker of cancer drugs used by Medicare, has been contacted by government and state officials, said company spokesman Jane Kramer. She wouldn't say whether the company is in settlement talks with the government.

Los Angeles Times Articles
|